Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Proof??? Since when did this board require proof of anything. Hell, even the CEOs quote at the top of the Ibox is a fabrication. Pretty scarey stuff. The caretakers of SMB falsifying the information. That's desperation.
Well, the company doesn't answer emails apparently. Probably to busy with all those clients.
Thanks, I write my own stuff.
Yes, he should retire. He could have a great second career playing the lead in the "Invisible Man" remake.
What board is this?......
Yep, been in for nearly 29 months. Check the chart. I'm doing just fine.
By three fold, IMO....$54 to $60
CTIX hits all time high $4.93
Yea, looks like it. One fugly chart.
Yeah, I said 8 to 10 EOY. I'm gonna stick to it.
Finally someones attention
CTIX CONTINUES TO MOVE UPWARD...UP ANOTHER 5%
MORE CTIX NEWS!!!!
BEVERLY, MA--(Marketwired - Dec 10, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the US Food and Drug Administration (FDA) has agreed that Cellceutix may begin a Phase 2 study of Prurisol (abacavir acetate), a potential chronic oral therapy for the treatment of placque psoriasis. Cellceutix conducted a Phase 1 study which demonstrated that the bioavailability of the active component of Prurisol (abacavir) was the same or lower than that of the marketed drug Ziagen® (abacavir sulfate). FDA noted at the end-of-Phase 1 meeting on December 8, 2014 that, pending the full review of the Phase 1 data, long-term safety data for Prurisol in the treatment of psoriasis would not be required.
Prurisol will be eligible for the 505(b)(2) drug approval pathway for the treatment of psoriasis. A potential application to market Prurisol will contain safety and efficacy data from studies conducted by Cellceutix, but at least some of the information required for approval may come from studies not conducted by Cellceutix. In this case, the long term safety data for Ziagen, marketed for over 15 years in the US, will be referenced.
"We are excited to enter the next phase of clinical development for Prurisol," stated Leo Ehrlich, Chief Executive Officer of Cellceutix. "There is a need for additional non-biologic treatments for chronic psoriasis and we think Prurisol has great potential based on our earlier results in an animal model of psoriasis. We look forward to the many important events happening this month at Cellceutix."
Yes, $4.70 seems to be a line n someone's sand....
I believe the QDIP designation has provisions in regard to patents to enable B to be exclusive to CTIX,for an extended period of time.
Exactly. What relevant information was gathered? Yes, JCDS has a credibility problem. They choose to have this problem.
BTW, altering the quote at the top of the Ibox and attributing it to the CEO doesn't do much for the credibility of the company or the IBox. Unless someone can find that quote in a PR somewhere, I an assuming it's been fabricated and attributed to the CEO.
"Our intent is to Release or Announce on-or-by our Fiscal Year-End, June 30, 2014." -- Cary Allen, CEO of JC Data Solutions, Inc.
May 22,2014
???????
CTIX up nearly 30% as FDA grants QIDP status.
CTIX AT ALL TIME HIGHS!!!
If they can find a way to coat every implanted device with B to,either totally prevent or to at the least minimize the potential for infection that would be huge. The money hospitals and liability carriers would save would be incredible.
Very rarely do successful companies, or even companies close to being successful, stay dark. Pretty much any degree of success is disseminated to shareholders in short order.
Silence is rarely golden.
Still no response. Probably on vacation.
I took my position in CTIX 2 yrs ago because of the promise of K. Leo's move on Poly and the advancement of B will go down as one of the savvy business moves in bio history IMO. AND we still have P moving along nicely. The moon may only be a pit stop.
GLTA!!!
I sent two emails to the company two days ago requesting information. No reply as of yet.
CCNI getting a quick feel....HOD on above ave volume.
Biotech segment coming up on cnbc
WHere was the quote at the beginning of the Ibox from?. It says May 22 2014.
I cannot find any press release from May 22 2014.
Is the following factual? Was this an actual quote from the CEO?
OR is this a false and misleading fabrication???
"Our intent is to Release or Announce on-or-by our Fiscal Year-End, June 30, 2014." -- Cary Allen, CEO of JC Data Solutions, Inc.
May 22,2014
I am waiting for a response from the company.
Yes, they are.
"Our intent is to Release or Announce on-or-by our Fiscal Year-End, June 30, 2014." -- Cary Allen, CEO of JC Data Solutions, Inc.
Was this an actual quote? I can't find it.
"We are very busy with JC Data and its two new companies. We have hired a project manager for our Appeal Manager(TM) product to handle sales and training. Regarding the stock, we have not sold stock into the market for several years now and we don't plan to for some time. Our intentions are to grow the company and have that in turn increase the value of the stock. iOur plan is still to show unaudited financials after our fiscal year end, June 2013," says Cary Allen, CEO JC Data Solutions, Inc.
Isn't that the actual quote from the Ibox?
Awaiting a reply.
http://www.bloomberg.com/news/2014-10-07/shale-boom-tested-as-sub-90-oil-threatens-u-s-drillers.html
So, I suppose there are differing opinions.
We will have to wait and see how,it plays out.
Thanks for the clarification and astute DD.
I agree EOY. But 2015 will be double your estimate IMO.
With the cost of oil plummeting, I expect many of the "clients" to start slashing jobs. How will that affect the "revenue" of JCDS?
Does anyone have any idea?
How is JCDS PAID?
Prolly 5mil shares. .10 a share PIPE prolly.
When the stroke fest is,over maybe some,of,you homos can start talking about stocks instead of jerking each others peckers.
Ancient history. Stock is only as good as its last tick. Ad the last few ticks have sucked.
But they have a lot of clients. Have you not looked at the Ibox? They have so many clients they need increased sales staff...
Apparently the CEO doesn't feel creating value to shareholders is very important. Oh and reporting earnings and such....well,they are to busy servicing all their clients to be bothered with all those types of small details.
Whatta joke.
CCNI getting more love ....